clinical trial · NCT06655883
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)
Merck Sharp & Dohme LLC·phase3·recruiting·n = 300
InsomniaSuvorexantPlacebo
brief summary
People with opioid use disorder (OUD) can have trouble falling or staying asleep. Researchers want to know if suvorexant will help people with OUD fall asleep and stay asleep. The goal of this study is to learn about the safety of suvorexant and how well people tolerate it. Researchers also want to learn if suvorexant helps people sleep longer compared to people who take placebo. A placebo looks like the study medicine but has no actual study medicine in it.
started
Oct 9, 2025
primary completion
Jun 24, 2027
completion
Jun 24, 2027
last updated
May 15, 2026
official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol